Paul Swiecicki, MD
Manage Your Profile
About
My career is dedicated to reducing cancer’s burden on patients through translational research and collaborative clinical trials. My clinical and research interests are primarily in head and neck cancer and early-stage therapeutics. These interests stem from the remarkable heterogeneity tumor biology and patient outcomes within a single disease entity, paired with often ineffective therapeutics. My research has focused on development of novel therapeutics for advanced head and neck cancer, biomarker development, and treatment de-escalation strategies in patients with low-risk human papillomavirus related oropharyngeal cancer. My career began by studying small molecule inhibitors in metastatic head and neck cancer which led to development of numerous funded multi-institution investigator initiated clinical trials as a PI. Development of these trials has equipped me with the necessary administrative skills needed for collaborative science including multi-institutional communication, budgeting, and regulatory management. I am the PI of a pivotal multisite investigator-initiated registration trial evaluating MDM-2 inhibition in metastatic salivary gland cancer as well as a co-PI of the NCI iMATCH Feasibility Study S2101 investigating biomarker stratified treatment of advanced solid tumors. Given my research experience, involvement with the head and neck community, and translational research I was appointed to the NCI Recurrent/Metastatic Head and Neck Task Force. In the Spring of 2020, I was also appointed as Co-Director of the University of Michigan Experimental Therapeutics/Phase 1 Program.
Center Memberships
-
Center MemberRogel Cancer Center
Research Overview
1) Novel therapeutics and treatment strategies for advanced / metastatic diseases including head and neck cancer.
2) Biomarker development in head and neck squamous cell carcinoma.
3) Tumor immune microenvironment modulation in advanced head and neck cancer.
Recent Publications
-
Pearson AT, Muzaffar J, Kirtane K, Bellile E, Suresh K, Rosenberg AJ, Worden F, Chung CH, Vokes E, Brenner JC, Bhangale A, McHugh J, Warner K, Nor F, Nor JE, Innes K, Zhai Y, Fu T, Swiecicki PL. Nature Communications, 2026 Dec 1; 17 (1):Journal ArticleMDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: a phase I clinical trial
DOI:10.1038/s41467-026-70653-3 PMID: 41857036 -
Kassamali B, Schoenfeld JD, Sethi R, Bakst RL, Barker CA, Bhatt AA, Bradford CR, Bunch PM, Carr DR, Carucci JA, Chandra S, Chen M, Connolly KL, Demer AM, Doonan B, Emerick K, Friedman BJ, Gali LL, Galloway TJ, Geiger JL, Guenette JP, Kelly HR, Khushalani NI, Kohen L, Koyfman S, Kumar SS, Learned KO, Leitenberger JJ, Lilley EJ, Lukens JN, Medina T, Mitra D, Ozog D, Pashtan I, Patel VA, Pham N, Powers MC, Srivastava D, Swiecicki PL, Taylor CS, Witek ME, Wysong A, Zander D, Silk AW, Jambusaria-Pahlajani A, Ruiz ES. JAMA Dermatology, 2026 Sep 16; 162 (9): 939 - 947.Journal ArticleConsensus Guidelines for Staging and Surveillance Imaging in Cutaneous Squamous Cell Carcinoma
DOI:10.1001/jamadermatol.2026.2163 PMID: 42418212 -
Kao H-F, Harrington K, Bhatia A, Wang H-M, Sandhu MS, Ince W, Pawlowska E, Vidales Z, Oliva M, Mehta A, Swiecicki PL, Ahn M-J, Sukari A, Kim S-B, Lin J-C, Keam B, Lyu X, Curtin JC, Toyoizumi K, Wade M, Kapoor A, Lorenzini P, Yilmaz E, Baig M, Verheijen RB, Shah S, Mehra R. Clin Cancer Res, 2026 Sep 15;Journal ArticleAmivantamab plus pembrolizumab in previously untreated recurrent/metastatic head and neck squamous cell cancer: Results from the phase 1b/2 OrigAMI-4 study.
DOI:10.1158/1078-0432.CCR-26-1372 PMID: 42742405 -
Higgins L, Suresh K, Wilkins S, Lyden T, Blakely A, Ambrose M, Elliott DA, Strohbehn G, Prince ME, Casper K, Shuman A, Stucken CL, Forner D, Heft-Neal ME, Yalamanchi P, Brenner C, Swiecicki PL, Worden F, Mierzwa ML, Shah JL. International Journal of Radiation Oncology • Biology • Physics, 2026 Sep 27; 126 (1): e689 - e690.Journal ArticleTwelve-Month Swallowing Outcomes in a Phase II Trial of PET-Adapted Radiation for HPV-Associated Oropharynx Squamous Cell Carcinoma
DOI:10.1016/j.ijrobp.2026.06.2147 -
Higgins L, Suresh K, Shah JL, Nasser B, Casper K, Prince ME, Forner D, Buchakjian M, Heft-Neal ME, Yalamanchi P, Rosen BS, Shuman A, Stucken CL, Brenner C, D'Silva N, Swiecicki PL, Worden F, Mierzwa ML. International Journal of Radiation Oncology • Biology • Physics, 2026 Sep 27; 126 (1): e689Journal ArticleUMCC 2023.006: A Pilot Phase II Trial of Individualized FDG-PET and DCE-MRI Directed Adaptive RT in HPV-related Stage III Oropharynx Cancer
DOI:10.1016/j.ijrobp.2026.06.2146 -
Burtness B, Rosenberg AJ, Calderon B, Lim SM, Yang MH, Li SH, Kadowaki S, Swiecicki PL, Geiger JL, Ince W, Hahn D, Guo Y, Adkins D, Metcalf R, Ahn MJ, Sukari A, Braña I, Keam B, Tanaka H, Sheth S, Oliva M, Lyu X, Curtin JC, Toyoizumi K, Xie J, Wade M, Diorio B, Kapoor A, Yilmaz E, Baig M, Kim P, Verheijen RB, Shah S, Harrington KJ, Abdeddaim , Abdeddaim C, Adkins D, Ahn MJ, Bhatia A, Braña I, Calderon B, Forster M, Geiger J, Guo Y, Hahn D, Haigentz M, Harrington K, Iglesias L, Ince W, Ji D, Kadowaki S, Kawecki A, Keam B, Kerrigan K, Kim SB, Li SH, Lim SM, Lin JC, Liu L, McDermott J, Metcalf R, Pawlowska E, Rosenberg A, Rutkowski T, Sandhu M, Shariff NM, Sheth S, Spira A, Sukari A, Swiecicki PL, Tanaka H, Viala C, Vidales Z, Wang HM, Yang MH, Yang K. Journal of Clinical Oncology, 2026 Aug 20; 44 (24): 2271 - 2277.Journal ArticleAmivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study
DOI:10.1200/JCO-26-01042 PMID: 42218660 -
Swiecicki PL, Hanna GJ, Geiger JL, Fujisawa T, Haigentz M, Honma Y, Bruce JY, Tanaka K, Muro K, Bhateja P, Kaplan J, Liu S, Gorla S, Wozniak M, Dillon R, Hamed S, Meng C, Chaney MF, Rosenberg AJ. Clinical Cancer Research, 2026 Aug 15; 32 (16): 3531 - 3539.Journal ArticleEnfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9
DOI:10.1158/1078-0432.CCR-25-4650 PMID: 42084607 -
Koyfman SA, Bauman JE, Mohseni M, Amit M, Dadhania DM, Demehri S, Divi V, Geiger JL, Hanna GJ, Kushalani N, Lipson EJ, Mannon RB, Migden M, Schmalbach CE, Swiecicki PL, Tayar JH, Tsai KY, Wuthrick EJ, Malik S, Gross ND. J Natl Cancer Inst, 2026 Jul 21;Journal ArticleSummary recommendations from the NCI clinical trials planning meeting (CTPM) on advanced cutaneous squamous cell carcinoma in immunosuppressed patients.
DOI:10.1093/jnci/djag240 PMID: 42478754
Featured News & Stories
Phase 1 trial of alrizomadlin shows promise in targeting metastatic salivary gland cancers
